Whitehawk Therapeutics (WHWK) Non-Current Assets (2016 - 2026)
Whitehawk Therapeutics (WHWK) reported Non-Current Assets of $1.7 million for Q1 2026, up 21.25% year-over-year from $1.4 million in Q1 2025, and down 7.37% on a QoQ basis from $1.8 million in Q4 2025.
Whitehawk Therapeutics (WHWK) has 11 years of Non-Current Assets data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Non-Current Assets rose 21.25% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (down 72.16% YoY) and the FY2025 annual result came in at $1.8 million, down 79.88% from the prior year.
- Non-Current Assets fell to $1.7 million in Q1 2026 per WHWK's latest filing, from $1.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $9.0 million in Q4 2024 and bottomed at $1.4 million in Q1 2025.
- The 5-year median for Non-Current Assets is $5.7 million (2023), against an average of $5.3 million.
- The widest annual swing landed in 2022, when Non-Current Assets jumped 14503.42%; it then slumped 83.67% in 2025.
- Tracing WHWK's Non-Current Assets over 5 years: stood at $4.2 million in 2022, then surged by 86.24% to $7.8 million in 2023, then rose by 15.25% to $9.0 million in 2024, then plunged by 79.88% to $1.8 million in 2025, then fell by 7.37% to $1.7 million in 2026.
- Per Business Quant, the three latest WHWK Non-Current Assets figures stand at $1.7 million (Q1 2026), $1.8 million (Q4 2025), and $2.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Whitehawk Therapeutics | 312.26 Mn | 189.22 Mn | - | 1.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.68 Mn |
| Dec 31, 2025 | 1.82 Mn |
| Sep 30, 2025 | 1.98 Mn |
| Jun 30, 2025 | 2.15 Mn |
| Mar 31, 2025 | 1.39 Mn |
| Dec 31, 2024 | 9.03 Mn |
| Sep 30, 2024 | 8.38 Mn |
| Jun 30, 2024 | 8.62 Mn |
| Mar 31, 2024 | 8.50 Mn |
| Dec 31, 2023 | 7.84 Mn |
| Sep 30, 2023 | 6.78 Mn |
| Jun 30, 2023 | 6.31 Mn |
| Mar 31, 2023 | 5.72 Mn |
| Dec 31, 2022 | 4.21 Mn |
| Sep 30, 2022 | 4.24 Mn |
| Jun 30, 2022 | 4.30 Mn |
| Mar 31, 2022 | 6.70 Mn |
| Dec 31, 2021 | 6.64 Mn |
| Sep 30, 2021 | 6.75 Mn |
| Jun 30, 2021 | 29,452.00 |
| Mar 31, 2021 | 162,110.00 |
| Dec 31, 2020 | 140,000.00 |
| Sep 30, 2020 | 247,086.00 |
| Jun 30, 2020 | 280,930.00 |
| Mar 31, 2020 | 307,905.00 |
| Dec 31, 2019 | 366,311.00 |
| Sep 30, 2019 | 747,421.00 |
| Jun 30, 2019 | 810,713.00 |
| Mar 31, 2019 | 757,678.00 |
| Dec 31, 2018 | 139,409.00 |
| Sep 30, 2018 | 122,251.00 |
| Jun 30, 2018 | 113,016.00 |
| Mar 31, 2018 | 124,151.00 |
| Dec 31, 2017 | 128,183.00 |
| Sep 30, 2017 | 137,833.00 |
| Jun 30, 2017 | 149,986.00 |
| Mar 31, 2017 | 159,107.00 |
| Dec 31, 2016 | 170,555.00 |